-
Mallinckrodt Reports Better-Than-Expected Q1, Raises Guidance
Tuesday, February 2, 2016 - 8:54am | 263Read More...Shares of Mallinckrodt PLC (NYSE: MNK) were trading higher by nearly 6 percent early Tuesday morning after the company reported its first quarter results. Mallinckrodt earned $2.09 per share in the first quarter on revenue of $914.80 million. Wall Street analysts were expecting the company to...
-
Biogen's Stock Pops Following Better-Than-Expected Q4 Results
Wednesday, January 27, 2016 - 9:37am | 399Read More...Shares of Biogen Inc (NASDAQ: BIIB) were trading higher by more than 5 percent early Wednesday morning after the company reported its fourth quarter and full year results. Biogen earned $4.50 per share in the fourth quarter on revenue of $2.839 billion. Wall Street analysts were expecting the...
-
BioCryst Pharmaceuticals Highly Volatile
Tuesday, January 26, 2016 - 11:32am | 113Read More...Baker Brothers Advisors, a hedge fund run by Julian and Felix Baker, disclosed after Monday's market close it acquired 106,800 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) for $7.28 per share. BioCryst Pharmaceuticals is a biotechnology company that develops small molecule drugs...
-
Relypsa Up 10% Following Encouraging Phase 1 Study Results
Tuesday, January 26, 2016 - 9:30am | 262Read More...Shares of Relypsa Inc (NASDAQ: RLYP), a biopharmaceutical company that focuses on non-absorbed polymeric drugs to tread disorders in the areas of renal, cardiovascular and metabolic diseases, were trading higher by more than 10 percent early Tuesday morning. Relypsa announced after Monday's close...
-
OncoMed Pharma Crashes 40% After Poor Trial Data
Monday, January 25, 2016 - 10:19am | 254Read More...Shares of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) plunged 42 percent during Monday's pre-market session after the company provided an update on its Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data...
-
AstraZeneca Shares Higher Following Barclays Upgrade
Tuesday, January 19, 2016 - 10:42am | 311Read More...Shares of AstraZeneca plc (ADR) (NYSE: AZN) have declined 15.04 percent over the past one year, from $35.89 on January 20, 2015. Barclays’ Mark Purcell has upgraded the rating on the company from Underweight to Equal Weight, while raising the price target from £44 to £50...
-
Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'
Monday, January 11, 2016 - 2:57pm | 171Read More...Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) were trading lower by nearly 7 percent at $78.74 mid-Monday afternoon after the company announced its pipeline goals for 2016 across its various segments. Alnylam Pharmaceuticals noted that by the end of 2020 it expects to achieve a profile...
-
Every Biotech Catalyst Wedbush Is Watching In 2016
Saturday, January 2, 2016 - 9:20pm | 826Read More...In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals stock under the firm’s coverage. Overall, Wedbush is very bullish about these 11 Outperform-rated stocks headed into 2016. Carbylan Therapeutics Inc (NASDAQ: CBYL) Wedbush...
-
Teva Pharmaceutical: Joint Venture With Takeda Will Be 'Instantly Accretive' To 2016 EPS And Beyond
Monday, December 28, 2015 - 10:55am | 211Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) established a joint business venture with Japan-based Takeda Pharmaceutical Company at the end of November. The companies updated the investment community on Sunday and offered details of their strategic partnership. According to a joint...
-
Adamas Pharmaceuticals Surges 30% Following Positive Phase 3 Results
Wednesday, December 23, 2015 - 9:49am | 184Read More...Shares of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) spiked higher by more than 30 percent early Wednesday after the company announced positive top-line Phase 3 results of ADS-5102 for patients with Parkinson's Disease. Adamas Pharmaceuticals said that results from its randomized, placebo-...
-
Bill Ackman: Valeant Is 'Enormously' Undervalued
Wednesday, December 16, 2015 - 10:31am | 484Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have gained more than 45 percent over the past month, but are still lower by around 24 percent since the start of 2015. Valeant's stock crashed to a multi-year low of $69.33 following scathing allegations from Citron Research, statements from...
-
Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds
Saturday, December 12, 2015 - 3:05pm | 705Read More...The global pharmaceutical industry has experienced a plethora of successful new products within the sector, more than offsetting global pricing pressures and supporting an outlook change to positive from stable for the entire industry. JPMorgan projects several important product launches and...
-
HIV Diagnoses Are Falling
Tuesday, December 8, 2015 - 10:31am | 436Read More...The Washington Post, citing a Centers for Disease Control and Prevention study, reported the number of annual HIV diagnoses has dropped by 19 percent between 2005 and 2014. Men who have sex with other men accounted for around 67 percent of all HIV diagnoses in 2014. HIV cases among women fell by...
-
Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas
Tuesday, December 8, 2015 - 9:29am | 850Read More...Liana Moussatos of Wedbush overviewed the emerging pharmaceuticals space and offered a scenario analysis of various potential catalysts. Moussatos has the highest degree of confidence on two upcoming catalysts for Relypsa Inc (NASDAQ: RLYP), one of which could see its stock move up or down by as...
-
Mylan To Lose Hostile Takeover Of Perrigo
Friday, November 13, 2015 - 10:03am | 326Read More...Shares of Mylan NV (NASDAQ: MYL) surged higher by 10 percent early Friday morning while shares of Perrigo Company plc Ordinary Shares (NYSE: PRGO) lost more than 11 percent. Mylan's acquisition of Perrigo was contingent on at least 50 percent of Perrigo's shareholders tendering their...
